Results from two new phase III trials, CheckMate 025 and METEOR, show that patients with advanced-stage, pretreated clear cell renal cell carcinoma (ccRCC) derive increased survival benefits from ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback